DaleLeeBixbyMD

Oncology • Ann Arbor, MI

Hematologic Oncology

Assistant Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Bixby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bixby's full profile

Already have an account?

Office
1500 E Medical Center Dr
Ann Arbor, MI 48109
Phone+1 734-936-4000

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2006 - 2009
University of MichiganResidency, Internal Medicine, 2003 - 2006
University of Michigan Medical SchoolClass of 2003

Certifications & Licensure

MI State Medical License 2003 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia Start of enrollment: 2007 Sep 01
Terminated
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha Start of enrollment: 2009 May 01
Terminated
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. Start of enrollment: 2013 Sep 01
Withdrawn
Phase 1, Phase 2
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Mar 20
Completed
Phase 1
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia Start of enrollment: 2024 Jun 03
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring.
Taylor D Coe-Eisenberg, Anthony J Perissinotti, Bernard L Marini, Kristen M Pettit, Dale L Bixby
Annals of Hematology. 2023-11-01
6 citations
Utility of methicillin-resistant staphylococcus aureus (MRSA) nasal screening in patients with acute myeloid leukemia (AML).
Millicynth Talagtag, Twisha S Patel, Gianni B. Scappaticci, Anthony J. Perissinotti, Allison J Schepers
Transplant Infectious Disease. 2021-04-07
19 citations
The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
Vera Vulaj, Anthony J. Perissinotti, James R. Uebel, Victoria R Nachar, Gianni B. Scappaticci
Leukemia Research. 2018-07-01

Journal Articles

The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid Leukemia
Dale L Bixby, Ivan P Maillard, Moshe Talpaz, Leukemia Research
A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML
Dale L. Bixby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...
Dale L. Bixby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integr...
Dale L. Bixby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid LeukemiaJune 2018

Press Mentions

Clinical Challenges: Preventing Early Mortality in Acute Promyelocytic LeukemiaMay 2nd, 2022
New Study in JNCCN Finds Disturbing Lack of Key Leukemia MedicationNovember 16th, 2021
ASH 2016 – Monday, December 5December 5th, 2015
Join now to see all